Fast Five Quiz: ERBB2 (HER2) Mutation in Non-Small Cell Lung Cancer

Maurie Markman, MD


November 23, 2021

Oncogenic mutations and amplifications in ERBB2 are detected by next-generation sequencing in 2%-4% of patients with NSCLC and are associated with constitutive HER2 activation.

Learn more about HER2 mutations in NSCLC.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.